The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 24, 2020

Filed:

Jul. 25, 2018
Applicant:

Duke University, Durham, NC (US);

Inventors:

Herbert K. Lyerly, Durham, NC (US);

Takuya Osada, Durham, NC (US);

Zachary C. Hartman, Durham, NC (US);

Assignee:

DUKE UNIVERSITY, Durham, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07H 21/04 (2006.01); A61K 38/45 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/001106 (2018.08); A61K 38/45 (2013.01); A61K 39/0011 (2013.01); A61K 39/001102 (2018.08); A61K 39/001104 (2018.08); A61K 39/3955 (2013.01); C07H 21/04 (2013.01); C07K 16/2818 (2013.01); C12N 7/00 (2013.01); C12Y 207/10001 (2013.01); A61K 2039/53 (2013.01); C07K 2317/76 (2013.01); C12N 2740/15034 (2013.01); C12N 2740/15043 (2013.01);
Abstract

Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent.


Find Patent Forward Citations

Loading…